rs45608937

Variant summary

Our verdict is Uncertain significance. The variant received 3 ACMG points: 3P and 0B. PM1PP3

The NM_001276345.2(TNNT2):​c.481C>T​(p.Arg161Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000548 in 1,460,296 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R161H) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000055 ( 0 hom. )

Consequence

TNNT2
NM_001276345.2 missense

Scores

14
5
1

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:10

Conservation

PhyloP100: 1.20

Publications

13 publications found
Variant links:
Genes affected
TNNT2 (HGNC:11949): (troponin T2, cardiac type) This gene encodes the cardiac isoform of troponin T. The encoded protein is the tropomyosin-binding subunit of the troponin complex, which is located on the thin filament of striated muscles and regulates muscle contraction in response to alterations in intracellular calcium ion concentration. Mutations in this gene have been associated with familial hypertrophic cardiomyopathy as well as with dilated cardiomyopathy. [provided by RefSeq, May 2022]
TNNT2 Gene-Disease associations (from GenCC):
  • dilated cardiomyopathy
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • dilated cardiomyopathy 1D
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics
  • hypertrophic cardiomyopathy
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • hypertrophic cardiomyopathy 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • hypertrophic cardiomyopathy 3
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • cardiomyopathy, familial restrictive, 3
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • familial isolated dilated cardiomyopathy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial isolated restrictive cardiomyopathy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • left ventricular noncompaction
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • cardiomyopathy
    Inheritance: AR Classification: LIMITED Submitted by: Ambry Genetics
  • arrhythmogenic right ventricular cardiomyopathy
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 3 ACMG points.

PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 22 uncertain in NM_001276345.2
PP3
MetaRNN computational evidence supports a deleterious effect, 0.81

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TNNT2NM_001276345.2 linkc.481C>T p.Arg161Cys missense_variant Exon 11 of 17 ENST00000656932.1 NP_001263274.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TNNT2ENST00000656932.1 linkc.481C>T p.Arg161Cys missense_variant Exon 11 of 17 NM_001276345.2 ENSP00000499593.1

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD2 exomes
AF:
0.00000402
AC:
1
AN:
248806
AF XY:
0.00000742
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000886
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000548
AC:
8
AN:
1460296
Hom.:
0
Cov.:
31
AF XY:
0.00000413
AC XY:
3
AN XY:
726474
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33470
American (AMR)
AF:
0.00
AC:
0
AN:
44704
Ashkenazi Jewish (ASJ)
AF:
0.0000383
AC:
1
AN:
26120
East Asian (EAS)
AF:
0.0000504
AC:
2
AN:
39692
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86072
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52284
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5742
European-Non Finnish (NFE)
AF:
0.00000360
AC:
4
AN:
1111896
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60316
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
33
Alfa
AF:
0.0000364
Hom.:
0

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:10
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Cardiomyopathy Uncertain:2
Mar 28, 2024
All of Us Research Program, National Institutes of Health
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 04, 2019
Color Diagnostics, LLC DBA Color Health
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This missense variant replaces arginine with cysteine at codon 151 of the TNNT2 protein. Computational prediction tool suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold ≥0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 27532257) and in two individuals affected with dilated cardiomyopathy (PMID: 19412328, 21483645). This variant has been identified in 1/248806 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

Primary dilated cardiomyopathy Pathogenic:1
Mar 01, 2024
Lildballe Lab, Aarhus University Hospital
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

PP2(m) PP1(m) PP3(sup) -

not specified Uncertain:1
May 31, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: TNNT2 c.451C>T (p.Arg151Cys) results in a non-conservative amino acid change located in the Tm binding domain (Hershberger_2009) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250588 control chromosomes (gnomAD and publication data). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.451C>T has been reported in the literature in individuals affected with dilated cardiomyopathy, hypertrophic cardiomyopathy and left ventricular noncompaction cardiomyopathy, as well as in unaffected individuals in one family (Hershberger_2008, Hershberger_2009, Walsh_2016, Ware_2018, Liu_2019, Mazzarotto_2020, Carnevale_2020). At least one functional study reports this variant results in decreased Ca2+ sensitivity in skinned cardiac muscle fibers (Hershberger_2009). Two ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -

Dilated cardiomyopathy 1D Uncertain:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Uncertain:1
Oct 11, 2022
Mayo Clinic Laboratories, Mayo Clinic
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

BS4, PP3, PM2_supporting, PS3_supporting, PS4_moderate -

Cardiomyopathy, familial restrictive, 3 Uncertain:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypertrophic cardiomyopathy 2 Uncertain:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Cardiovascular phenotype Uncertain:1
Jun 21, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.R151C variant (also known as c.451C>T), located in coding exon 9 of the TNNT2 gene, results from a C to T substitution at nucleotide position 451. The arginine at codon 151 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was reported as homozygous in an individual with dilated cardiomyopathy (DCM); however, her homozygous sibling and three heterozygous family members were unaffected (Hershberger RE et al. Clin Transl Sci, 2008 May;1:21-6). This variant has also been detected in DCM and hypertrophic cardiomyopathy genetic testing cohorts as well as a left ventricular noncompaction cohort; however, clinical details were limited (Walsh R et al. Genet. Med., 2017 02;19:192-203; Rieger AC et al. EBioMedicine, 2019 Oct;48:377-385; Liu S et al. Int J Cardiol. 2020 Mar;302:117-123; Mazzarotto F et al. Circulation. 2020 Feb;141(5):387-398). One study indicated this variant may impact protein function through altered calcium sensitivity, but the clinical impact of these findings has not been demonstrated (Hershberger RE et al. Circ Cardiovasc Genet, 2009 Aug;2:306-13). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Dilated cardiomyopathy 1D;C1861864:Hypertrophic cardiomyopathy 2;C2676271:Cardiomyopathy, familial restrictive, 3 Uncertain:1
Dec 27, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 151 of the TNNT2 protein (p.Arg151Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with dilated cardiomyopathy, hypertrophic cardiomyopathy, and/or left ventricular noncompaction (PMID: 20031601, 27532257, 31918855, 31983221; Invitae). ClinVar contains an entry for this variant (Variation ID: 537256). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNNT2 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

TNNT2-related disorder Uncertain:1
Oct 10, 2022
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The TNNT2 c.451C>T variant is predicted to result in the amino acid substitution p.Arg151Cys. This variant was reported in the homozygous state in an individual with idiopathic dilated cardiomyopathy; however, the variant was also found in the homozygous state in an asymptomatic sibling and both unaffected parents were heterozygous (Hershberger et al 2008. PubMed ID: 19412328; Hershberger RE et al 2009. PubMed ID: 20031601). This variant was also reported in a familial case of dilated cardiomyopathy (Carnevale A et al 2020. PubMed ID: 32969603) and in one case from a large cohort study of patients with dilated cardiomyopathy (Mazzarotto F et al 2020. PubMed ID: 31983221). The c.451C>T was also reported in a patient with left ventricular noncompaction cardiomyopathy; however, the patient carried additional variants in other relevant cardiac genes (Table S1 in Liu S et al 2019. PubMed ID: 31918855). This variant is reported in 0.00089% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-201333434-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.57
CardioboostCm
Uncertain
0.73
BayesDel_addAF
Pathogenic
0.28
D
BayesDel_noAF
Pathogenic
0.17
CADD
Pathogenic
32
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.96
.;.;.;.;D;.;.;.;.;.;D;.
Eigen
Uncertain
0.65
Eigen_PC
Uncertain
0.55
FATHMM_MKL
Uncertain
0.90
D
LIST_S2
Pathogenic
0.99
.;D;D;D;D;D;D;.;.;D;.;.
M_CAP
Pathogenic
0.89
D
MetaRNN
Pathogenic
0.81
D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
0.98
D
MutationAssessor
Pathogenic
2.9
.;.;.;.;M;.;.;.;.;.;.;.
PhyloP100
1.2
PrimateAI
Uncertain
0.72
T
PROVEAN
Pathogenic
-6.5
D;D;.;D;D;.;.;.;D;D;D;D
REVEL
Pathogenic
0.82
Sift
Pathogenic
0.0
D;D;.;D;D;.;.;.;D;D;D;D
Sift4G
Pathogenic
0.0
D;D;D;D;D;D;D;D;D;D;.;D
Polyphen
1.0
.;.;.;.;D;.;.;.;.;.;D;.
Vest4
0.64
MutPred
0.44
.;.;.;.;Loss of MoRF binding (P = 0.014);.;.;.;.;.;.;Loss of MoRF binding (P = 0.014);
MVP
0.95
MPC
1.6
ClinPred
0.97
D
GERP RS
4.3
Varity_R
0.38
gMVP
0.98
Mutation Taster
=0/100
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
2.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs45608937; hg19: chr1-201333434; COSMIC: COSV99372078; COSMIC: COSV99372078; API